Reference Source

Welip (M) Sdn Bhd · 66-41 · MALAYSIA

For Welip (M) Sdn Bhd · 66-41 · MALAYSIA, import alert is 66-41; import alert name is Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S; country is MALAYSIA; product is Linsen Double Caulis Capsules; product code is 54 Y - - 99 Vitamin, Mineral, Proteins and Unconventional Dietary Specialities For Humans and Animals, N.E.C; date published is 10/22/2025; address is NO.10, Jalan TTC 26 , Taman Teknologi Cheng , Melaka, Melaka MALAYSIA, verified against its source on 2026-09-16.

Firm
Welip (M) Sdn Bhd verified
Import alert
66-41
Import alert name
Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S.
Country
MALAYSIA verified
Address
NO.10, Jalan TTC 26 , Taman Teknologi Cheng , Melaka, Melaka MALAYSIA verified
Date published
10/22/2025 verified
Product code
54 Y - - 99 Vitamin, Mineral, Proteins and Unconventional Dietary Specialities For Humans and Animals, N.E.C. verified
Product
Linsen Double Caulis Capsules verified
FDA notes
Linsen Double Caulis Capsules is a drug as defined by section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is an article intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure or function of the body. Statements in product labeling that provide evidence of the intended use of the product include, but may not be limited to, the following: “Traditionally used for relief of backache, lumbago, sinew and cartilage.” verified
Sourceaccessdata.fda.gov
Verified
Review by
DatasetFDA import alert red lists: firms subject to detention without physical examination

What the source says

Welip (M) Sdn Bhd Date Published : 10/22/2025 NO.10, Jalan TTC 26 , Taman Teknologi Cheng , Melaka, Melaka MALAYSIA 54 Y - - 99 Vitamin, Mineral, Proteins and Unconventional Dietary Specialities For Humans and Animals, N.E.C. Date Published: 10/22/2025 Desc: Linsen Double Caulis Capsules Notes: Linsen Double Caulis Capsules is a drug as defined by section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is an article intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure or function of the body. Statements in product labeling that provide evidence of the intended use of the product include, but may not be limited to, the following: “Traditionally used for relief of backache, lumbago, sinew and cartilage.”

accessdata.fda.gov, retrieved 2026-09-15

The same source also states

Welip (M) Sdn Bhd Date Published : 12/24/2013 Lot 1892 Riverview Arcade Kuchin , Sarawak, MALAYSIA 66 V - - 99 Miscellaneous Patent Medicines, Etc. Date Published: 12/24/2013 Desc: Ceng Fui Yen 66 V - - 99 Miscellaneous Patent Medicines, Etc. Date Published: 12/24/2013 Desc: Kian Pee Wah

accessdata.fda.gov, retrieved 2026-09-15

Source

Last verified against source: . Due for re-check by . This page as Markdown · OKF bundle · full dataset as JSON.

This one changes, and we watch it.FDA import alert red lists: firms subject to detention without physical examination is re-read on a schedule and every change is dated. Subscribe: Atom feed · JSON · what has changed so far.